Bipolar Electrode Array for Multiplexed Detection of Prostate Cancer Biomarkers

Anal Chem. 2022 Feb 15;94(6):3005-3012. doi: 10.1021/acs.analchem.1c05383. Epub 2022 Feb 1.

Abstract

Owing to the characteristics of high throughput, high flexibility, and convenient separation of the sensing and reporting reactions, the bipolar electrode (BPE) shows great potential in clinical analysis. However, there are some difficulties in the combination of BPEs and multiplex electrochemiluminescence (ECL) biosensing, such as the need for small sample consumption, multistep operations, and separated sample loading. In this paper, a microfluidic BPE array chip was fabricated toward multiplex detection of cancer biomarkers. With a special channel structure and the difference in flow resistance of channels of different sizes, the direction of liquid flow was successfully controlled. In this way, rapid and automatic multiplex sampling was achieved on the array, which would help improve the sensing efficiency and reduce the reagent consumption. The ECL BPE array chip served as an immunosensor for multiple prostate cancer biomarkers including prostate-specific antigen (PSA), interleukin-6 (IL-6), and prostate-specific membrane antigen (PSMA). The microfluidic BPE chip shows good reproducibility and high sensitivity. The limits of detection for PSA, IL-6, and PSMA are 0.093 ng/mL, 0.061 pg/mL, and 0.059 ng/mL, respectively. It also exhibits excellent performance in real sample analysis. The integrated ECL BPE array shows a good application prospect in clinical sensing of cancer biomarkers, as well as point-of-care testing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / analysis
  • Biosensing Techniques* / methods
  • Electrochemical Techniques / methods
  • Electrodes
  • Humans
  • Immunoassay
  • Luminescent Measurements / methods
  • Male
  • Prostate / chemistry
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / diagnosis
  • Reproducibility of Results

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen